Concentration(s) Common formulations:- **PT-141 Injectable:** 10 mg/mL reconstituted solution- **Sermorelin Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL- **GHK-Cu Topical:** 0.1% 3%- **NAD+ Injectable:** 100 mg/mL 500 mg/mL- **Oral Troche (PT-141, Sermorelin, NAD+):** 0.5-2 mg per dose Maximum Dosage (Day, Wk) Recommended maximum doses:- **PT-141:** 1.75 mg subcutaneous per dose, max 2 doses per week- **Sermorelin:** 200-500 mcg subcutaneous per dose, daily- **GHK-Cu:** Apply 1-2 times daily- **NAD+:** 50-500 mg subcutaneous per dose, 1-3x per week Contraindications Pregnancy, breastfeeding, active cancer, history of pituitary tumors, cardiovascular disease (for PT-141), history of melanoma (for GHK-Cu), uncontrolled hypertension, or hypersensitivity to any of the compounds
4 Glucagon-like peptide-1 receptor The GLP-1R comprises seven hydrophobic transmembrane domains and a hydrophilic extracellular domain [41]
Glutathione in these fractions were alkalized and derivatized with 6-aminoquinolyl-N hydroxy succinimidyl carbamate as described previously
This plant will manufacture weight-loss injectables (tirzepatide and related peptides like retatrutide) and associated devices
Slominski A, Paus R (1993) Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth